Citadel Advisors’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Citadel Advisors’s Portfolio FMTX Stock Details FMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11,219	Closed	-$224K	–	16053
2022 Q3	$224K	Sell	11,219 -1,086,525	-99%	-$14.3M	﹤0.01%	10183
2022 Q2	$7.56M	Buy	1,097,744 +677,615	+161%	+$4.76M	﹤0.01%	3068
2022 Q1	$3.91M	Buy	420,129 +349,997	+499%	+$3.73M	﹤0.01%	4658
2021 Q4	$998K	Buy	+70,132	New	+$1.21M	﹤0.01%	7963
2021 Q2	–	Sell	-24,555	Closed	-$688K	–	14765
2021 Q1	$688K	Sell	24,555 -12,791	-34%	-$462K	﹤0.01%	8980
2020 Q4	$1.3M	Buy	+37,346	New	+$1.63M	﹤0.01%	6232

Citadel Advisors's FMTX Position: Q4 2022 in Review

Citadel Advisors sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 11,219 shares — an estimated $224K sold.

Citadel Advisors first reported a position in FMTX in Q4 2020 and held it in 6 quarters. The position peaked at $7.56M in Q2 2022. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

Citadel Advisors reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Citadel Advisors sold 11,219 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $224K.
Citadel Advisors first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
Citadel Advisors's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $7.56M in Q2 2022.
0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.